| Identification | Back Directory | [Name]
CYM 2503 | [CAS]
1308833-36-4 | [Synonyms]
CYM 2503
L-Lysinamide, 3-cyclohexyl-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-alanyl-N-(1,2-dihydro-4-methyl-2-oxo-7-quinolinyl)-N6-[(1,1-dimethylethoxy)carbonyl]-
(9H-FLUOREN-9-YL)METHYL((S)-1(((S)-6(TERTBUTOXYCARBONYL) AMINO-1-((4-METHYL-2-OXO-1,2-DIHYDROQUINOLIN-7-YL)AMINO)-1-OXOHEXAN-2-YL)AMINO))-3-CYCLOHEXYL-1-OXOPROPAN-2-YL) CARBAMATE | [Molecular Formula]
C45H55N5O7 | [MDL Number]
MFCD31618422 | [MOL File]
1308833-36-4.mol | [Molecular Weight]
777.95 |
| Chemical Properties | Back Directory | [Boiling point ]
1009.4±65.0 °C(Predicted) | [density ]
1.210±0.06 g/cm3(Predicted) | [form ]
A solid | [pka]
10.68±0.46(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
CYM2503 is a putative GalR2-positive allosteric modulator. CYM2503 increases the latency to first electrographic seizure and decreases the total time in seizure. CYM2503 also attenuates electroshock-induced seizures in mice. Galanin receptors type 1 (GalR1) and/or type 2 (GalR2) represent unique pharmacological targets for the research of seizures and epilepsy[1]. | [References]
[1] Lu X, et al. GalR2-positive allosteric modulator exhibits anticonvulsant effects in animal models. Proc Natl Acad Sci U S A. 2010;107(34):15229-15234. DOI:10.1073/pnas.1008986107 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|